Loading
Lymphoma has more trials open to it than almost any other cancer, and in several situations a trial is a reasonable choice beside standard treatment rather than a last resort. Asking early keeps the option open, because many trials require that a particular treatment has not yet been given.
**Why the question comes early in this disease.** Almost every standard lymphoma treatment in use today was set by a trial a patient agreed to join, and the places where practice is least settled are the places where a trial is open: first-line treatment of advanced Hodgkin lymphoma, early-relapsing large B-cell lymphoma, follicular lymphoma that progresses within two years, mantle cell lymphoma, and nearly all of the peripheral T-cell lymphomas. Lymphoma Action runs a lymphoma-specific trials database, Lymphoma TrialsLink, with a free enquiry service.
**The practical reason to ask on the first visit.** Most trials specify what treatment a person may already have had. A trial of a first-line treatment closes to you the day the first-line treatment starts, and a trial for people who have had one previous treatment closes after the second. The NHS trials page sets out what taking part involves, that participation is voluntary and that you can leave at any time without affecting your care.
**What taking part is actually like.** Lymphoma Action's page on taking part describes the consent process, the extra visits, scans and blood tests that most trials add, the travel, and the right to withdraw. It is honest about the asymmetry: a randomised trial exists because nobody knows which arm is better, so joining one is not the same as being given the better treatment, and the benefit to the person taking part is uncertain even when the benefit to the next patient is not.
**Two questions that are worth asking out loud.** First, whether a trial that is not open at this hospital is open at another, and whether the team will refer. Second, what happens to travel and accommodation costs, which many trials reimburse and few people are told about unprompted.
Showing the technology this term belongs to: Multidisciplinary tumour boards.
Shares Early-stage classical Hodgkin lymphoma (stage I to II), Relapsed and refractory classical Hodgkin lymphoma, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Early-stage classical Hodgkin lymphoma (stage I to II), Relapsed and refractory classical Hodgkin lymphoma, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Primary CNS lymphoma.
Shares Primary CNS lymphoma, Waldenström macroglobulinaemia, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma.
Shares Early-stage classical Hodgkin lymphoma (stage I to II), Relapsed and refractory classical Hodgkin lymphoma, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Primary CNS lymphoma.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Waldenström macroglobulinaemia, Marginal zone lymphoma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
Shares Waldenström macroglobulinaemia, Marginal zone lymphoma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma.
Shares Early-stage classical Hodgkin lymphoma (stage I to II), Relapsed and refractory classical Hodgkin lymphoma, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Waldenström macroglobulinaemia.
Shares Early-stage classical Hodgkin lymphoma (stage I to II), Advanced-stage classical Hodgkin lymphoma (stage III to IV), Burkitt lymphoma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).